检索结果-南通市图书馆

Comparative Pharmacokinetic Study between metformin Alone and Combined with Orlistat in Healthy mexican Volunteers

维普期刊数据库

同方期刊数据库评论

在线全文

学校读者我要写书评

暂无评论

Pharmacology & Pharmacy 2012年第3期3卷 300-306页

作者： noem. Santos-Caballero Francisco Javier Flores-murrieta Landsteiner Scientific S.A. de C.V. México D.F. Mexico Sección de Estudios de Posgrado e Investigación Escuela Superior de Medicina Instituto Politécnico Nacional México D.F. Mexico

Traditional treatment of type 2 diabetes mellitus (T2Dm) has focused on correcting hyperglycemia. However, T2Dm is almost always accompanied by other conditions and risk factors that affect its morbidity and mortality. Obesity represents one of the main risk factors associated in the T2Dm and a modest weight loss around 5% is linked with significant reduction in the blood glucose levels. The objective of this study was to compare the pharmacokinetic parameters between two formulations of metformin, alone or combined with orlistat, in healthy volunteers. A single-blinded, single dose, two-period, two-sequence, crossover, randomized and balanced study design with a 7-day washout period was performed in 26 mexican volunteers. Plasma samples were collected over a 24-hour period after administration of 500 mg metformin alone or combined with 60 mg orlistat in each period. A validated high-performance liquid chromatography coupled with a ultraviolet detector was used to analyze metformin concentration in plasma. Bioequivalence between metformin alone and metformin combined with orlistat was determined when the ratio for the 90% confidence intervals (CI) of area under the curve (AUC24h) and maximum concentration (Cmax) of the two formulations were within 80% and 125%. In the current study, the mean ± standard deviation (SD) of Cmax, AUC24h and AUC∞ of the formulation containing only metformin were 1.39 ± 0.44 μg/mL, 7.59 ± 3.17 μg h/mL and 8.48 ± 4.13 μg h/mL, respectively, while the mean ± SD of Cmax, AUC24h and AUC∞ of the formulation containing metformin and orlistat were 1.38 ± 0.48 μg/mL, 7.80 ± 2.83 μg h/mL and 9.13 ± 4.29 μg h/mL, respectively. The parametric 90% CI for Cmax and AUC24h were 87.5-109.3 and 88.7-124.7, respectively. These results suggest that both formulations are bioequivalent and there is not pharmacokinetic interaction between metformin and orlistat.

关键词： metformin Orlistat Diabetes Obesity Bioequivalence Pharmacokinetic

Safety and Efficacy of Oral mirodenafil in mexican with Erectile Dysfunction

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

International Journal of Clinical medicine 2016年第9期7卷 628-638页

作者： Juan Gerardo Reyes-García noem. Santos-Caballero Francisco Javier Flores-murrieta Sección de Estudios de Posgrado e Investigación Escuela Superior de Medicina Instituto Politécnico Nacional Ciudad de México Mexico Landsteiner Scientific S.A. de C.V. Ciudad de México Mexico Unidad de Investigación en Farmacología Instituto Nacional de Enfermedades Respiratorias “Ismael Cosio Villegas” Ciudad de México Mexico

Erectile dysfunction is treated with 5-phospodiesterase inhibitors as mirodenafil, which has shown its efficacy and safety in Koreans, however;no information in other populations is available. An open clinical trial study was designed to evaluate the efficacy and safety in real life of a fixed-dose of mirodenafil in mexican patients with erectile dysfunction. Forty-seven male patients received a 100 mg tablet of mirodenafil, during 12 weeks. Primary outcome efficacy measure was the percentage of male patients with successful intercourse. Secondary outcomes measures included patient satisfaction, mood and self-esteem level. Safety assessments included laboratory tests, vital signs, physical examination, 12-lead electrocardiogram recordings, and incidence of adverse events by patients. Oral administration of mirodenafil improved in an 80% - 90% the number of successful intercourses from 7 to 84 days of treatment. moreover, patients reported a significant increment in their sexual satisfaction, mood and self-esteem. mirodenafil treatment did not modify vital signs nor anthropometric parameters during 84 days. mild headache was the most frequent adverse event (17.0%) and there were no severe adverse events during pharmacological treatment. Data suggest that oral mirodenafil is safety, well tolerated and effective in the mexican population with erectile dysfunction.

关键词： Efficacy Erectile Dysfunction mexicans mirodenafil Safety

Expression of triggering receptor on myeloid cell 1 and histocompatibility complex molecules in sepsis and major abdominal surgery

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

World Journal of Gastroenterology 2005年第47期11卷 7473-7479页

作者： Nestor González-Roldán Eduardo Ferat-Osorio Rosalía Aduna-Vicente Isabel Wong-Baeza noem. Esquivel-Callejas Horacio Astudillo-de la Vega Patricio Sánchez-Fernández Lourdes Arriaga-Pizano miguel Angel Villasís-Keever Constantino López-macías Armando Isibasi Unidad de Investigación médica en Inmunoquímica Hospital de EspecialidadesCentro Médico Nacional Siglo ⅩⅪInstituto Mexicano del Seguro Social (IMSS)México Laboratorio de Oncología molecular Unidad de Investigación Médica en Enfermedades OncológicasHospital de OncologíaCentro Médico Nacional Siglo ⅩⅪIMSSMéxico Servicio de Gastrocirugía Hospital de EspecialidadesCentro Médico Nacional Siglo ⅩⅪIMSSMéxico Unidad de Investigación en Epidemiología Clínica Hospital de PediatríaCentro Médico Nacional Siglo ⅩⅪIMSSMéxico

AIm： To evaluate the surface expression of triggering receptor on myeloid cell 1 （TREm-1）, class Ⅱ major histocompatibility complex molecules （HLA-DR）, and the expression of the splicing variant （svTREH-1） of TREm-1 in septic patients and those subjected to major abdominal surgery. mETHODS： Using flow cytometry, we examined the surface expression of TREm-1 and HLA-DR in peripheral blood monocytes from 11 septic patients, 7 elective gastrointestinal surgical patients, and 10 healthy volunteers, svTREm-1 levels were analyzed by RT-PCR. RESULTS： Basal expression of TREm-1 and HLA- DR in healthy volunteers was 35.91±14.75 mFI and 75.8±18.3%, respectively. In septic patients, TREm-1 expression was 59.9±23.9 mFI and HLA-DR expression was 44.39±20.25%, with a significant difference between healthy and septic groups （P〈0.05） for both molecules. In the surgical patients, TREm-1 and HLA-DR expressions were 56.8±20.85 HFI and 71±13.8% before surgery and 72.65±29.92 mFI and 72.82±22.55% after surgery. TREm-1 expression was significantly different （P = 0.0087） between the samples before and after surgery and svTREm-1 expression was 0.8590± 0.1451 mF1, 0.8820±0.1460 mF1, and 2.210±0.7873 mF1 in the healthy, surgical （after surgery） and septic groups, respectively. There was a significant difference （P = 0.048） in svTREm-1 expression between the healthy and surgical groups and the septic group. CONCLUSION： TREm-1 expression is increased during systemic inflammatory conditions such as sepsis and the postoperative phase. Simultaneous low expression of HLA-DR molecules correlates with the severity of illness and increases susceptibility to infection. Additionally, TREm-1 expression is distinctly different in surgical patients at different stages of the inflammatory response before and after surgery. Thus, surface TREm-1 appears to be an endogenous signal during the course of the inflammatory response, svTREm-1 expression is significantly increased during sepsis, appearing to be a

关键词： TRFm-1 HLA-DR SIRS CARS Sepsis

Oral Pharmacokinetics of mirodenafil in mexican Healthy Volunteers

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Pharmacology & Pharmacy 2014年第1期5卷 112-116页

作者： miriam del Carmen Carrasco-Portugal Francisco Javier Flores-murrieta Juan Gerardo Reyes-García noem. Santos-Caballero Landsteiner Scientific S.A. de C.V. México DF México Sección de Estudios de Posgrado e Investigación Escuela Superior de Medicina Instituto Politécnico Nacional México DF México Unidad de Investigación en Farmacología Insituto Nacional de Enfermedades Respiratorias “Ismael Cosio Villegas” México DF México Unidad de Investigación en Farmacología Insituto Nacional de Enfermedades Respiratorias “Ismael Cosio Villegas” México DF México Sección de Estudios de Posgrado e Investigación Escuela Superior de Medicina Instituto Politécnico Nacional México DF México

mirodenafil is a 5-phosphodiesterase inhibitor that is currently marketed in Korea for the treatment of erectile dysfunction;however, no information in other populations is available. It has been described that mirodenafil is metabolized by CYP3A4, a metabolic pathway in which interethnic differences have been reported. The purpose of this study was to characterize the oral pharmacokinetics of mirodenafil in mexicans. Seventeen male healthy volunteers were enrolled in this study. After an overnight fast, volunteers received an oral 100 mg dose and blood samples were collected at selected times during 24 h. Plasma was stored frozen and analyzed by an HPLC method. Pharmacokinetic parameters obtained were: Cmax 331.129 ± 32.689 ng/mL, tmax 1.574 ± 0.293 h, AUC24h 883.293 ± 104.088 ng·h/mL, AUC￥ 976.477 ± 108.812 ng·h/mL and t1/2 1.807 ± 0.171 h. Parameter values observed in this study are similar to those reported in Koreans. Since efficacy and safety studies of mirodenafil have been conducted in Koreans, it is expected that dosage regime to employ in mexicans should be similar to the approved for Korean population.

关键词： Erectile Dysfunction Healthy Volunteers mexican mirodenafil Pharmacokinetic